Saruta Y, Watanabe K, Tsuji T, Takahashi Y, et al. Vonoprazan poses no additional risk of developing Clostridioides difficile infection compared to proton pump inhibitors. J Gastroenterol Hepatol 2023 Mar 7. doi: 10.1111/jgh.16169.
PMID: 36882162